Figure 4. Effects of exogenous T-cell
cytokine receptor (TCCR) on human umbilical vein endothelial
cells (HUVECs). A: After HUVECs were treated with
recombinant human TCCR/WSX-1/Fc chimera protein for 8 h, tube
formation was detected with phase contrast microscopy. Twenty
percent fetal bovine serum (FBS) was used as a control. B:
The number of tubes was quantified by counting the total tubes
per five fields in a blinded manner. C: western blot
using antibody against ERK, phosphorylated extracellular
signal-regulated kinase (ERK), and β-actin from HUVECs that were
treated with 100 pM recombinant TCCR or control IgG for the
indicated times.